Cargando…
Intratumoral Th2 predisposition combines with an increased Th1 functional phenotype in clinical response to intravesical BCG in bladder cancer
Th1-type immunity is considered to be required for efficient response to BCG in bladder cancer, although Th2 predisposition of BCG responders has recently been reported. The aim was to evaluate the relationship of Th1 and Th2 components in 23 patients undergoing BCG treatment. Peripheral blood, seru...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5359386/ https://www.ncbi.nlm.nih.gov/pubmed/28005163 http://dx.doi.org/10.1007/s00262-016-1945-z |
_version_ | 1782516377827934208 |
---|---|
author | Pichler, Renate Gruenbacher, Georg Culig, Zoran Brunner, Andrea Fuchs, Dietmar Fritz, Josef Gander, Hubert Rahm, Andrea Thurnher, Martin |
author_facet | Pichler, Renate Gruenbacher, Georg Culig, Zoran Brunner, Andrea Fuchs, Dietmar Fritz, Josef Gander, Hubert Rahm, Andrea Thurnher, Martin |
author_sort | Pichler, Renate |
collection | PubMed |
description | Th1-type immunity is considered to be required for efficient response to BCG in bladder cancer, although Th2 predisposition of BCG responders has recently been reported. The aim was to evaluate the relationship of Th1 and Th2 components in 23 patients undergoing BCG treatment. Peripheral blood, serum and urine samples were prospectively collected at baseline, during and after BCG. Th1 (neopterin, tryptophan, kynurenine, kynurenine-to-tryptophan ratio (KTR), IL-12, IFN-γ, soluble TNF-R75 and IL-2Rα) and Th2 (IL-4, IL-10) biomarkers as well as CD4 expression in T helper (Th), effector and regulatory T cells were determined. Local immune cell subsets were measured on formalin-fixed, paraffin-embedded cancer tissue by immunohistochemistry to examine expression of transcription factors that control Th1 (T-bet) and Th2-type (GATA3) immunity. We confirmed a Th2 predisposition with a mean GATA3/T-bet ratio of 5.51. BCG responders showed significantly higher levels of urinary (p = 0.003) and serum neopterin (p = 0.012), kynurenine (p = 0.015), KTR (p = 0.005), IFN-γ (p = 0.005) and IL-12 (p = 0.003) during therapy, whereas levels of IL-10 decreased significantly (p < 0.001) compared to non-responders. GATA3/T-bet ratio correlated positively with serum neopterin (p = 0.008), IFN-γ (p = 0.013) and KTR (p = 0.018) after the first BCG instillation. We observed a significant increase in CD4 expression in the Th cell population (p < 0.05), with only a modest tendency toward higher frequency in responders compared to non-responders (p = 0.303). The combined assessment of GATA3/T-bet ratio, neopterin and KTR may be a useful biomarker in predicting BCG response. Th2-promoting factors such as GATA3 may trigger Th1-type immune responses and thus contribute to the BCG success. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00262-016-1945-z) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5359386 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-53593862017-04-04 Intratumoral Th2 predisposition combines with an increased Th1 functional phenotype in clinical response to intravesical BCG in bladder cancer Pichler, Renate Gruenbacher, Georg Culig, Zoran Brunner, Andrea Fuchs, Dietmar Fritz, Josef Gander, Hubert Rahm, Andrea Thurnher, Martin Cancer Immunol Immunother Original Article Th1-type immunity is considered to be required for efficient response to BCG in bladder cancer, although Th2 predisposition of BCG responders has recently been reported. The aim was to evaluate the relationship of Th1 and Th2 components in 23 patients undergoing BCG treatment. Peripheral blood, serum and urine samples were prospectively collected at baseline, during and after BCG. Th1 (neopterin, tryptophan, kynurenine, kynurenine-to-tryptophan ratio (KTR), IL-12, IFN-γ, soluble TNF-R75 and IL-2Rα) and Th2 (IL-4, IL-10) biomarkers as well as CD4 expression in T helper (Th), effector and regulatory T cells were determined. Local immune cell subsets were measured on formalin-fixed, paraffin-embedded cancer tissue by immunohistochemistry to examine expression of transcription factors that control Th1 (T-bet) and Th2-type (GATA3) immunity. We confirmed a Th2 predisposition with a mean GATA3/T-bet ratio of 5.51. BCG responders showed significantly higher levels of urinary (p = 0.003) and serum neopterin (p = 0.012), kynurenine (p = 0.015), KTR (p = 0.005), IFN-γ (p = 0.005) and IL-12 (p = 0.003) during therapy, whereas levels of IL-10 decreased significantly (p < 0.001) compared to non-responders. GATA3/T-bet ratio correlated positively with serum neopterin (p = 0.008), IFN-γ (p = 0.013) and KTR (p = 0.018) after the first BCG instillation. We observed a significant increase in CD4 expression in the Th cell population (p < 0.05), with only a modest tendency toward higher frequency in responders compared to non-responders (p = 0.303). The combined assessment of GATA3/T-bet ratio, neopterin and KTR may be a useful biomarker in predicting BCG response. Th2-promoting factors such as GATA3 may trigger Th1-type immune responses and thus contribute to the BCG success. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00262-016-1945-z) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2016-12-22 2017 /pmc/articles/PMC5359386/ /pubmed/28005163 http://dx.doi.org/10.1007/s00262-016-1945-z Text en © The Author(s) 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Article Pichler, Renate Gruenbacher, Georg Culig, Zoran Brunner, Andrea Fuchs, Dietmar Fritz, Josef Gander, Hubert Rahm, Andrea Thurnher, Martin Intratumoral Th2 predisposition combines with an increased Th1 functional phenotype in clinical response to intravesical BCG in bladder cancer |
title | Intratumoral Th2 predisposition combines with an increased Th1 functional phenotype in clinical response to intravesical BCG in bladder cancer |
title_full | Intratumoral Th2 predisposition combines with an increased Th1 functional phenotype in clinical response to intravesical BCG in bladder cancer |
title_fullStr | Intratumoral Th2 predisposition combines with an increased Th1 functional phenotype in clinical response to intravesical BCG in bladder cancer |
title_full_unstemmed | Intratumoral Th2 predisposition combines with an increased Th1 functional phenotype in clinical response to intravesical BCG in bladder cancer |
title_short | Intratumoral Th2 predisposition combines with an increased Th1 functional phenotype in clinical response to intravesical BCG in bladder cancer |
title_sort | intratumoral th2 predisposition combines with an increased th1 functional phenotype in clinical response to intravesical bcg in bladder cancer |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5359386/ https://www.ncbi.nlm.nih.gov/pubmed/28005163 http://dx.doi.org/10.1007/s00262-016-1945-z |
work_keys_str_mv | AT pichlerrenate intratumoralth2predispositioncombineswithanincreasedth1functionalphenotypeinclinicalresponsetointravesicalbcginbladdercancer AT gruenbachergeorg intratumoralth2predispositioncombineswithanincreasedth1functionalphenotypeinclinicalresponsetointravesicalbcginbladdercancer AT culigzoran intratumoralth2predispositioncombineswithanincreasedth1functionalphenotypeinclinicalresponsetointravesicalbcginbladdercancer AT brunnerandrea intratumoralth2predispositioncombineswithanincreasedth1functionalphenotypeinclinicalresponsetointravesicalbcginbladdercancer AT fuchsdietmar intratumoralth2predispositioncombineswithanincreasedth1functionalphenotypeinclinicalresponsetointravesicalbcginbladdercancer AT fritzjosef intratumoralth2predispositioncombineswithanincreasedth1functionalphenotypeinclinicalresponsetointravesicalbcginbladdercancer AT ganderhubert intratumoralth2predispositioncombineswithanincreasedth1functionalphenotypeinclinicalresponsetointravesicalbcginbladdercancer AT rahmandrea intratumoralth2predispositioncombineswithanincreasedth1functionalphenotypeinclinicalresponsetointravesicalbcginbladdercancer AT thurnhermartin intratumoralth2predispositioncombineswithanincreasedth1functionalphenotypeinclinicalresponsetointravesicalbcginbladdercancer |